Pantoprazol Biofarmoz (Pantoprazole)

Pantoprazol Biofarmoz is a proton pump inhibitor that acts on the gastric acid secretion pathway.

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining.
• Erosive oesophagitis: accelerates mucosal healing and reduces further erosion.
• Peptic ulcer disease: supports ulcer healing and helps prevent recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.
• Helicobacter pylori eradication regimens: used as an adjunct to antibiotic therapy to improve eradication rates.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding irreversibly to this pump, it blocks the final step of acid production, leading to a sustained reduction in gastric acidity and an increase in gastric pH.

Pantoprazol Biofarmoz is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: typically self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: excess gas formation.
• Constipation: infrequent.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis.
• Clostridioides difficile infection: may present with severe diarrhea.
• Acute interstitial nephritis: renal inflammation requiring medical attention.
• Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia.
• Fracture risk: long‑term use may be associated with increased bone fracture incidence.
• Liver enzyme elevations: abnormal hepatic function tests.

When prescribing Pantoprazol Biofarmoz, clinicians should consider several safety aspects.

• Renal impairment: dose adjustment may be required in severe kidney disease.
• Hepatic impairment: use with caution in patients with liver dysfunction.
• Long‑term therapy: monitor for potential bone density loss and magnesium levels.
• Drug interactions: review concomitant medications for possible CYP‑mediated effects.
• Pregnancy and lactation: assess risk‑benefit ratio before use.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Pantoprazol Biofarmoz can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR values.
• Digoxin: altered absorption may require serum level monitoring.
• Methotrexate: increased systemic exposure, especially at high doses.